Insider trade

Director sold ~$493K of ARWR shares in the open market

Traded Nov 28, 2025 · Filed Dec 1, 2025

Why it stands out

A board member of Arrowhead Pharmaceuticals sold $493K of Arrowhead Pharmaceuticals shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$493,413

Shares × reported transaction price

Timing vs results

3 days after results of Nov 25, 2025, 69 days before results of Feb 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+18.8%	+0.2%	+18.6%
30 days	+17.0%	+0.2%	+16.7%
90 days	+11.0%	+0.7%	+10.3%
180 days	+29.8%	+11.3%	+18.5%

Past results only. Not a forecast.

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

9mo ago

Derivative exercise or conversion — not an open-market buy.

9mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance9mo ago